Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.76 Billion USD | 6.31% |
| 2022 | 1.96 Billion USD | 23.37% |
| 2021 | 1.89 Billion USD | -14.54% |
| 2020 | 1.07 Billion USD | 30.44% |
| 2019 | 1.3 Billion USD | -4.28% |
| 2018 | 1.15 Billion USD | 39.09% |
| 2017 | 1.1 Billion USD | 12.88% |
| 2016 | 890.6 Million USD | 36.28% |
| 2015 | 708.7 Million USD | 467.27% |
| 2014 | 563.4 Million USD | -145.69% |
| 2013 | 589.8 Million USD | -8.77% |
| 2012 | 452.8 Million USD | 33.92% |
| 2011 | 344.7 Million USD | 6.02% |
| 2010 | 327.1 Million USD | 25.59% |
| 2009 | 365.8 Million USD | 36.55% |
| 2008 | 227.2 Million USD | -29.94% |
| 2007 | 227.4 Million USD | 9.03% |
| 2006 | 230 Million USD | -18.79% |
| 2005 | 185.2 Million USD | -12.24% |
| 2004 | 320.2 Million USD | 47.97% |
| 2003 | 138.4 Million USD | 58.19% |
| 2002 | 92.5 Million USD | -13.42% |
| 2001 | 81.1 Million USD | -67.69% |
| 2000 | 169 Million USD | 148.22% |
| 1999 | 201 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 526.4 Million USD | -13.09% |
| 2024 Q3 | 402.8 Million USD | 2.88% |
| 2024 Q2 | 404.3 Million USD | 4.59% |
| 2023 Q3 | 422.8 Million USD | -25.72% |
| 2023 Q4 | 368.3 Million USD | -12.89% |
| 2023 FY | - USD | 6.31% |
| 2023 Q1 | 476.8 Million USD | 6.76% |
| 2023 Q2 | 569.2 Million USD | 19.38% |
| 2022 Q1 | 447.2 Million USD | 26.9% |
| 2022 FY | - USD | 23.37% |
| 2022 Q3 | 506.2 Million USD | 17.75% |
| 2022 Q2 | 429.9 Million USD | -3.87% |
| 2022 Q4 | 446.6 Million USD | -11.77% |
| 2021 FY | - USD | -14.54% |
| 2021 Q1 | 387.3 Million USD | 4.39% |
| 2021 Q3 | 401.9 Million USD | 17.62% |
| 2021 Q2 | 341.7 Million USD | -11.77% |
| 2021 Q4 | 352.4 Million USD | -12.32% |
| 2020 Q2 | 629.3 Million USD | 66.17% |
| 2020 Q1 | 378.7 Million USD | -1.07% |
| 2020 Q4 | 371 Million USD | 4.04% |
| 2020 Q3 | 356.6 Million USD | -43.33% |
| 2020 FY | - USD | 30.44% |
| 2019 Q4 | 382.8 Million USD | 25.3% |
| 2019 Q1 | 344.8 Million USD | -41.45% |
| 2019 Q2 | 297.5 Million USD | -13.72% |
| 2019 Q3 | 305.5 Million USD | 2.69% |
| 2019 FY | - USD | -4.28% |
| 2018 Q3 | 251.9 Million USD | -11.58% |
| 2018 FY | - USD | 39.09% |
| 2018 Q2 | 284.9 Million USD | 7.75% |
| 2018 Q1 | 264.4 Million USD | 69.38% |
| 2018 Q4 | 588.9 Million USD | 133.78% |
| 2017 Q1 | 320.9 Million USD | 52.23% |
| 2017 FY | - USD | 12.88% |
| 2017 Q4 | 156.1 Million USD | -31.51% |
| 2017 Q2 | 294.5 Million USD | -8.23% |
| 2017 Q3 | 227.9 Million USD | -22.61% |
| 2016 Q3 | 201.8 Million USD | -21.99% |
| 2016 Q2 | 258.7 Million USD | 20.83% |
| 2016 Q4 | 210.8 Million USD | 4.46% |
| 2016 Q1 | 214.1 Million USD | 20.28% |
| 2016 FY | - USD | 36.28% |
| 2015 FY | - USD | 467.27% |
| 2015 Q4 | 178 Million USD | 12.52% |
| 2015 Q2 | 147.8 Million USD | -10.8% |
| 2015 Q3 | 158.2 Million USD | 7.04% |
| 2015 Q1 | 165.7 Million USD | 2.73% |
| 2014 Q4 | 161.3 Million USD | 20.91% |
| 2014 Q3 | 133.4 Million USD | 123.08% |
| 2014 FY | - USD | -145.69% |
| 2014 Q2 | -578.1 Million USD | -642.82% |
| 2014 Q1 | 106.5 Million USD | -22.66% |
| 2013 Q2 | 122.3 Million USD | 372.2% |
| 2013 FY | - USD | -8.77% |
| 2013 Q4 | 137.7 Million USD | 35.93% |
| 2013 Q3 | 101.3 Million USD | -17.17% |
| 2013 Q1 | 25.9 Million USD | -81.62% |
| 2012 Q2 | 101.8 Million USD | 18.93% |
| 2012 Q1 | 85.6 Million USD | -18.01% |
| 2012 Q3 | 93.1 Million USD | -8.55% |
| 2012 FY | - USD | 33.92% |
| 2012 Q4 | 140.9 Million USD | 51.34% |
| 2011 Q3 | 62.2 Million USD | -22.73% |
| 2011 Q4 | 104.4 Million USD | 67.85% |
| 2011 Q1 | 72.2 Million USD | -24.87% |
| 2011 FY | - USD | 6.02% |
| 2011 Q2 | 80.5 Million USD | 11.5% |
| 2010 Q4 | 96.1 Million USD | 40.91% |
| 2010 FY | - USD | 25.59% |
| 2010 Q1 | 62.7 Million USD | -20.53% |
| 2010 Q2 | 73.6 Million USD | 17.38% |
| 2010 Q3 | 68.2 Million USD | -7.34% |
| 2009 FY | - USD | 36.55% |
| 2009 Q4 | 78.9 Million USD | 328.8% |
| 2009 Q3 | 18.4 Million USD | -72.33% |
| 2009 Q2 | 66.5 Million USD | -4.45% |
| 2009 Q1 | 69.6 Million USD | 11.0% |
| 2008 Q2 | 66.9 Million USD | 12.44% |
| 2008 FY | - USD | -29.94% |
| 2008 Q4 | 62.7 Million USD | 5.91% |
| 2008 Q3 | 59.2 Million USD | -11.51% |
| 2008 Q1 | 59.5 Million USD | -29.59% |
| 2007 Q2 | 60.7 Million USD | 7.05% |
| 2007 Q3 | 48 Million USD | -20.92% |
| 2007 Q1 | 56.7 Million USD | -26.08% |
| 2007 Q4 | 84.5 Million USD | 76.04% |
| 2007 FY | - USD | 9.03% |
| 2006 Q1 | 57 Million USD | -10.8% |
| 2006 Q2 | 59.7 Million USD | 4.74% |
| 2006 FY | - USD | -18.79% |
| 2006 Q3 | 56.7 Million USD | -5.03% |
| 2006 Q4 | 76.7 Million USD | 35.27% |
| 2005 Q4 | 63.9 Million USD | -16.69% |
| 2005 Q1 | 53.1 Million USD | -6.18% |
| 2005 Q2 | 87.6 Million USD | 64.97% |
| 2005 Q3 | 76.7 Million USD | -12.44% |
| 2005 FY | - USD | -12.24% |
| 2004 Q2 | 56.2 Million USD | -56.43% |
| 2004 FY | - USD | 47.97% |
| 2004 Q4 | 56.6 Million USD | -10.16% |
| 2004 Q3 | 63 Million USD | 12.1% |
| 2004 Q1 | 129 Million USD | 117.54% |
| 2003 Q4 | 50.7 Million USD | 3.13% |
| 2003 Q1 | 43.8 Million USD | 27.76% |
| 2003 Q2 | 31.1 Million USD | -14.81% |
| 2003 Q3 | 31.9 Million USD | 29.8% |
| 2003 FY | - USD | 58.19% |
| 2002 FY | - USD | -13.42% |
| 2002 Q2 | 40.7 Million USD | -41.85% |
| 2002 Q4 | 42 Million USD | 7.39% |
| 2002 Q3 | -30.8 Million USD | 77.1% |
| 2002 Q1 | 40.6 Million USD | 0.55% |
| 2001 Q2 | -36.3 Million USD | 17.36% |
| 2001 Q3 | 34.4 Million USD | -32.29% |
| 2001 FY | - USD | -67.69% |
| 2001 Q4 | 39.6 Million USD | 12.62% |
| 2001 Q1 | 43.3 Million USD | -31.95% |
| 2000 FY | - USD | 148.22% |
| 2000 Q1 | 46 Million USD | 2.13% |
| 2000 Q2 | 31 Million USD | 616.67% |
| 2000 Q3 | 39.7 Million USD | -85.67% |
| 2000 Q4 | 60.6 Million USD | 21.91% |
| 1999 FY | - USD | 0.0% |
| 1999 Q4 | 47 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 83.106% |
| Allurion Technologies Inc. | -69.03 Million USD | 2660.589% |
| Artivion, Inc. | 38.14 Million USD | -4534.261% |
| Avanos Medical, Inc. | 53.2 Million USD | -3222.556% |
| Butterfly Network, Inc. | -124.84 Million USD | 1515.847% |
| Butterfly Network, Inc. | -124.84 Million USD | 1515.847% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 390.597% |
| Boston Scientific Corporation | 3.45 Billion USD | 48.81% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 12012.657% |
| CONMED Corporation | 182.18 Million USD | -870.217% |
| Paragon 28, Inc. | -36.61 Million USD | 4927.662% |
| Glaukos Corporation | -82.11 Million USD | 2252.565% |
| Globus Medical, Inc. | 418.23 Million USD | -322.629% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 10461.079% |
| Integer Holdings Corporation | 282.05 Million USD | -526.677% |
| Medtronic plc | 9.05 Billion USD | 80.481% |
| Nevro Corp. | -78.31 Million USD | 2357.183% |
| Owlet, Inc. | -27.48 Million USD | 6530.208% |
| Penumbra, Inc. | 111.99 Million USD | -1478.271% |
| Vicarious Surgical Inc. | -69.19 Million USD | 2654.631% |
| Smith & Nephew plc | 979 Million USD | -80.552% |
| Sonendo, Inc. | -54.76 Million USD | 3327.432% |
| STERIS plc | 1.41 Billion USD | -25.148% |
| Stryker Corporation | 5.16 Billion USD | 65.744% |
| Vapotherm, Inc. | -34.35 Million USD | 5244.803% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 27.821% |